Owen Hughes Sells 21,881 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes sold 21,881 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the transaction, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

XOMA Trading Up 0.6 %

Shares of NASDAQ XOMA opened at $29.88 on Friday. The business has a 50-day moving average of $28.66 and a 200-day moving average of $26.86. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. XOMA Co. has a fifty-two week low of $14.33 and a fifty-two week high of $33.78.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $11.09 million during the quarter, compared to the consensus estimate of $8.37 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. As a group, sell-side analysts anticipate that XOMA Co. will post -0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On XOMA

Several hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its holdings in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the period. Ellsworth Advisors LLC bought a new position in XOMA during the third quarter worth about $516,000. Rhumbline Advisers grew its holdings in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 1,334 shares during the period. Bank of New York Mellon Corp grew its holdings in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares during the period. Finally, Price T Rowe Associates Inc. MD bought a new position in XOMA during the first quarter worth about $212,000. Institutional investors own 95.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and set a $117.00 target price on shares of XOMA in a report on Wednesday, October 23rd.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.